Multiple Myeloma trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Multiple Myeloma. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month6 studies across 6 companies, in the next 180 days.
August 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PFE | Pfizer | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)NCT06152575Progression free survival per International Myeloma Working Group criteria | Phase 3 | Recruiting | 2026-08-30 | in 10 d | 2026-08-14 |
| ABBV | AbbVie | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.NCT03539744Progression-Free Survival (PFS) | Phase 3 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2025-06-19 |
September 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaNCT04756726Phase 1: Safety and tolerability of cemsidomide | Phase 1 | Active, not recruiting | 2026-09-30 | in 41 d | 2026-03-25 |
| CGEM | Cullinan Therapeutics Inc. | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple MyelomaNCT06381141Proportion of participants reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Sep 2026 | ≤ 41 d | 2025-09-18 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaNCT05372354Number of participants with adverse events (AEs) | Phase 1/2 | Recruiting | 2026-10-12 | in 53 d | 2025-09-05 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaNCT04973605Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Nov 2026 | ≤ 102 d | 2026-08-07 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Multiple Myeloma
most recently updated first269 studies match. Showing the first 100 of 269 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AZN | AstraZeneca | — | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaNCT06106945Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only) | Phase 1/2 | Recruiting | Drug: AZD0305, Elranatamab, Pomalidomide, Dexamethasone | Multiple Myeloma | 226 | 2023-12-05 | 2027-08-16 | in 361 d | 2026-08-19 |
| AZN | AstraZeneca | — | AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)NCT05850234Phase 1b: Adverse Events (AEs) | Phase 1/2 | Recruiting | Biological: AZD0120 | Relapsed/Refractory Multiple Myeloma | 232 | 2023-07-20 | 2027-10-01 | in 407 d | 2026-08-17 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsNCT05020236Part 1 Safety Lead-In: Incidence of dose limiting toxicities | Phase 3 | Recruiting | Drug: Elranatamab, Daratumumab, Pomalidomide, Dexamethasone | Multiple Myeloma | 893 | 2021-10-04 | 2026-02-26actual | — | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple MyelomaNCT05259839Number of Participants with Dose Limiting Toxicities (DLT) of Etentamig | Phase 1 | Active, not recruiting | Drug: Etentamig, Dexamethasone, Lenalidomide, Pomalidomide, Daratumumab | Relapsed/Refractory Multiple Myeloma | 283 | 2022-10-20 | Sep 2033 | ≤ 2,598 d | 2026-08-14 |
| PFE | Pfizer | $155.3B | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)NCT06152575Progression free survival per International Myeloma Working Group criteria | Phase 3 | Recruiting | Drug: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib | Multiple Myeloma | 492 | 2024-02-08 | 2026-08-30 | in 10 d | 2026-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)NCT07409246Number of Participants With Adverse Events (AE) | Phase 1 | Recruiting | Drug: ABBV-438 | Multiple Myeloma | 127 | 2026-02-27 | Nov 2031 | ≤ 1,928 d | 2026-08-14 |
| PFE | Pfizer | $155.3B | A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple MyelomaNCT05675449Part 1 Number of participants with dose limiting toxicity (DLT) | Phase 1 | Active, not recruiting | Drug: Elranatamab, Carfilzomib, Maplirpacept | Multiple Myeloma | 59 | 2022-12-14 | 2026-03-11actual | — | 2026-08-13 |
| CCCC | C4 Therapeutics, Inc. | $514M | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma SubjectsNCT07280013Safety and tolerability of cemsidomide in combination with elranatamab | Phase 1 | Recruiting | Drug: Cemsidomide · Biological: Elranatamab | Multiple Myeloma (MM) | 60 | 2026-02-06 | Dec 2028 | ≤ 864 d | 2026-08-12 |
| ONC | BeOne Medicines | $545.6B | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaNCT04973605Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide | Relapsed/Refractory Multiple Myeloma | 246 | 2021-09-16 | Nov 2026 | ≤ 102 d | 2026-08-07 |
| CCCC | C4 Therapeutics, Inc. | $514M | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaNCT07284758Overall response rate (ORR) per International Myeloma Working Group (IMWG) Response Criteria by an Independent Review Committee (IRC) | Phase 2 | Recruiting | Drug: Cemsidomide, Dexamethasone | Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | 100 | 2026-02-18 | Mar 2030 | ≤ 1,319 d | 2026-08-06 |
| AZN | AstraZeneca | — | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)NCT07391657To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM. | Phase 3 | Recruiting | Biological: AZD0120 · Drug: Daratumumab, Carfilzomib, Dexamethasone, Bortezomib, Pomalidomide | Relapsed Refractory Multiple Myeloma | 508 | 2026-02-23 | 2028-06-14 | in 664 d | 2026-08-06 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple MyelomaNCT06669247Incidence of dose limiting toxicities (DLTs) from the first dose of REGN7945 in combination with linvoseltamab | Phase 1/2 | Recruiting | Drug: Linvoseltamab, REGN7945+Linvoseltamab | Relapsed/Refractory Multiple Myeloma | 186 | 2024-12-11 | 2033-11-11 | in 2,640 d | 2026-08-05 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple MyelomaNCT07455851Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamab | Phase 1/2 | Recruiting | Drug: Linvoseltamab, REGN17372+Linvoseltamab | Relapsed Refractory Multiple Myeloma (RRMM) | 150 | 2026-03-26 | 2033-09-30 | in 2,598 d | 2026-08-05 |
| ABBV | AbbVie | $457.5B | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT06158841Progression Free Survival (PFS) | Phase 3 | Recruiting | Drug: Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone | Multiple Myeloma | 380 | 2024-05-19 | Dec 2027 | ≤ 498 d | 2026-08-03 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)NCT07609940Occurrence of any grade CRS per American Society for Transplantation and Cellular Therapy (ASTCT) grading | Phase 4 | Recruiting | Drug: Linvoseltamab, Tocilizumab | Relapsed/Refractory Multiple Myeloma (RRMM) | 30 | 2026-07-15 | 2027-10-11 | in 417 d | 2026-07-29 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNCT07728188Safety Run-In: Number of Participants With Adverse Events (AE)s | Phase 3 | Not yet recruiting | Drug: Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab | Relapsed or Refractory Multiple Myeloma | 520 | 2026-11-30 | Feb 2033 | ≤ 2,384 d | 2026-07-27 |
| MRNA | ModernaTX, Inc. | $25.1B | A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaNCT07116616Number of Participants with Dose-limiting Toxicity | Phase 1/2 | Recruiting | Drug: mRNA-2808 | Relapsed or Refractory Multiple Myeloma | 166 | 2025-09-30 | 2030-06-17 | in 1,397 d | 2026-07-24 |
| ABBV | AbbVie | $457.5B | A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsNCT06892522Number of Participants with Adverse Events (AE)s | Phase 1/2 | Recruiting | Drug: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Dexamethasone, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001 | Multiple Myeloma | 602 | 2025-06-30 | Dec 2035 | ≤ 3,420 d | 2026-07-21 |
| LLY | Eli Lilly and Company | $1.15T | Study of Oral LOXO-338 in Patients With Advanced Blood CancersNCT05024045Part 1 - To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of oral LOXO-338 | Phase 1 | Completed | Drug: LOXO-338, Pirtobrutinib | Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell | 27 | 2021-09-30 | 2023-06-14actual | — | 2026-07-17 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Selinexor and Backbone Treatments of Multiple Myeloma PatientsNCT02343042Phase 1 (Dose-escalation): Maximum Tolerated Dose (MTD) | Phase 1/2 | Recruiting | Drug: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide | Multiple Myeloma | 300 | Oct 2015 | Apr 2027 | ≤ 253 d | 2026-07-15 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT05650632Arm A (Part 1 and Part 2) Arm C, and Arm D: Number of Grade >= 2 Cytokine Release Syndrome (CRS) Events | Phase 1 | Recruiting | Drug: Etentamig (ABBV-383) | Multiple Myeloma | 210 | 2023-03-21 | Aug 2029 | ≤ 1,107 d | 2026-07-13 |
| AZN | AstraZeneca | — | A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)NCT07073547Adverse Events (AEs) | Phase 1 | Recruiting | Biological: AZD0120 | Multiple Myeloma | 40 | 2025-07-31 | 2028-05-26 | in 645 d | 2026-07-13 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantNCT05623020Part 1 Dose Limiting Toxicity | Phase 3 | Recruiting | Drug: Elranatamab, Daratumumab, Lenalidomide, Dexamethasone, Bortezomib | Multiple Myeloma | 1,116 | 2022-11-10 | 2030-10-18 | in 1,520 d | 2026-07-09 |
| PFE | Pfizer | $155.3B | A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related DiseasesNCT05742217observationalReal-World Overall Response Rate (ORR) for each TCR MM therapy | — | Completed | — | Relapse Multiple Myeloma, Refractory Multiple Myeloma | 121 | 2023-05-26 | 2026-05-31actual | — | 2026-07-09 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsNCT05137054Incidence of Dose Limiting Toxicities (DLTs) for each study regimen during the observation period | Phase 1 | Recruiting | Drug: Linvoseltamab, Daratumumab, Carfilzomib, Lenalidomide, Bortezomib, Pomalidomide, Isatuximab, Fianlimab, Cemiplimab, Nirogacestat, Cevostamab | Multiple Myeloma | 317 | 2022-08-17 | 2028-03-25 | in 583 d | 2026-07-08 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple MyelomaNCT06140524Frequency of Adverse Events Interest (AEI) during the safety observation period | Phase 2 | Recruiting | Drug: Linvoseltamab | Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | 116 | 2024-09-16 | 2032-05-18 | in 2,098 d | 2026-07-08 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)NCT06953960Dose-Limiting Toxicities (DLT)s of ABBV-453 | Phase 1/2 | Recruiting | Drug: ABBV-453, Daratumumab, Dexamethasone, Pomalidomide | Multiple Myeloma | 199 | 2025-07-23 | Dec 2030 | ≤ 1,594 d | 2026-07-07 |
| BMY | Bristol-Myers Squibb | $134.9B | Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide RegimensNCT07689006observationalProgression-Free Survival (PFS) among participants who initiated pomalidomide-containing index regimens | — | Completed | Drug: Pomalidomide-containing regimens, Non-pomalidomide-containing regimens | Relapsed/Refractory Multiple Myeloma | 341 | 2024-12-23 | 2025-03-28actual | — | 2026-07-07 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaNCT05827016Progression-free survival (PFS) | Phase 3 | Active, not recruiting | Drug: Iberdomide, Lenalidomide | Multiple Myeloma | 1,230 | 2023-06-22 | 2029-03-15 | in 938 d | 2026-07-02 |
| AZN | AstraZeneca | — | A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaNCT07681596Adverse events (AEs) and serious AEs (SAEs) | Phase 1/2 | Not yet recruiting | Biological: AZD4045 · Drug: Daratumumab, Aldesleukin | Relapsed or Refractory Multiple Myeloma | 101 | 2026-07-09 | 2029-10-30 | in 1,167 d | 2026-07-02 |
| PFE | Pfizer | $155.3B | Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)NCT06057402Incidence of nonserious adverse events (AEs) leading to permanent discontinuation | Phase 4 | Recruiting | Drug: Elranatamab | Multiple Myeloma | 80 | 2023-10-03 | 2032-02-22 | in 2,012 d | 2026-07-01 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)NCT07428369Occurrence of Treatment-Emergent Adverse Events (TEAEs) | Phase 2/3 | Withdrawnsponsor's stated reason: Sponsor Decision | Drug: Linvoseltamab, Bortezomib, Lenalidomide, Daratumumab, Dexamethasone | Multiple Myeloma (MM) | 0 | 2026-06-05 | 2038-05-21 | in 4,292 d | 2026-06-18 |
| GERN | Geron Corporation | $983M | Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple MyelomaNCT01242930Rate of Improvement in Response | Phase 2 | Completed | Drug: Imetelstat (7.5 mg/kg), lenalidomide standard of care, Imetelstat (9.4 mg/kg) | Multiple Myeloma | 13 | Nov 2010 | Nov 2014actual | — | 2026-06-17 |
| ABBV | AbbVie | $457.5B | A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantNCT07095452Phase 2 and 3: Percentage of Participants with Adverse Events (AE)s | Phase 2/3 | Recruiting | Drug: Etentamig, Lenalidomide, Daratumumab, Dexamethasone, Dexamethasone | Multiple Myeloma | 660 | 2026-01-08 | Jan 2042 | ≤ 5,643 d | 2026-06-11 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)NCT06215118Part 1: Number of participants with dose limiting toxicity (DLT) | Phase 1 | Recruiting | Drug: Elranatamab, Iberdomide | Multiple Myeloma | 87 | 2024-02-20 | 2027-04-10 | in 233 d | 2026-06-10 |
| SNY | Sanofi | — | A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)NCT05839626Dose escalation (part 1a - RRMM) Presence of dose limiting toxicities (DLT) | Phase 1 | Terminatedsponsor's stated reason: Early discontinuation based on sponsor decision not driven by any safety concerns; phase 2 was not initiated. | Drug: SAR445514 | Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis | 32 | 2023-05-15 | 2025-05-26actual | — | 2026-05-27 |
| PFE | Pfizer | $155.3B | MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAbNCT04649359results2023-10-25Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) as Per International Myeloma Working Group (IMWG) Criteria | Phase 2 | Active, not recruiting | Drug: Elranatamab (PF-06863135) | Multiple Myeloma | 187 | 2021-02-02 | 2022-06-17actual | — | 2026-05-19 |
| IPH.PA | Innate Pharma | $170M | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple MyelomaNCT01222286results2014-05-09Rate of Patients Achieving an Objective Response | Phase 2 | Completed | Drug: IPH2101 | Smoldering Multiple Myeloma | 30 | Sep 2010 | Jul 2012actual | — | 2026-05-14 |
| ABBV | AbbVie | $457.5B | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialNCT03844048Number of Participants With Adverse Events | Phase 3 | Active, not recruiting | Drug: Venetoclax | Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer | 165 | 2019-09-06 | Aug 2027 | ≤ 376 d | 2026-05-13 |
| ALLO | Allogene Therapeutics | $701M | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)NCT04093596Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-715 | Phase 1 | Completed | Genetic: ALLO-715 · Biological: ALLO-647 · Drug: Fludarabine, Cyclophosphamide, Nirogacestat | Relapsed/Refractory Multiple Myeloma | 73 | 2019-09-23 | 2025-01-27actual | — | 2026-05-13 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received TreatmentNCT05828511Incidence of Dose-Limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: Linvoseltamab | Multiple Myeloma | 149 | 2023-12-19 | 2035-11-02 | in 3,361 d | 2026-05-13 |
| ABBV | AbbVie | $457.5B | Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT06896916Phase 1: Dose-Limiting Toxicities (DLT)s of Etentamig when given in Combination with Iberdomide in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 1 | Recruiting | Drug: Etentamig, Iberdomide | Multiple Myeloma | 135 | 2025-08-07 | Mar 2036 | ≤ 3,511 d | 2026-05-12 |
| AMGN | Amgen | $229.9B | Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple MyelomaNCT03934684results2024-01-02Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Phase 4 | Completed | Drug: Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide + Dexamethasone | Relapsed Refractory Multiple Myeloma | 101 | 2019-09-16 | 2023-03-23actual | — | 2026-05-11 |
| REGN | Regeneron Pharmaceuticals | $76.1B | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)NCT04083534Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period | Phase 1/2 | Completed | Drug: REGN5459 | Relapsed Multiple Myeloma, Refractory Multiple Myeloma | 43 | 2019-09-26 | 2025-05-01actual | — | 2026-05-04 |
| PFE | Pfizer | $155.3B | MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple MyelomaNCT05090566results2026-02-23SSA: Number of Participants With Dose Limiting Toxicities (DLTs)- Phase 1b Dose Escalation | Phase 2 | Terminatedsponsor's stated reason: A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities. | Drug: Elranatamab + Nirogacestat, Elranatamab + lenalidomide + dexamethasone | Multiple Myeloma | 46 | 2021-10-27 | 2025-02-13actual | — | 2026-04-24 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple MyelomaNCT03761108Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period | Phase 1/2 | Recruiting | Drug: Linvoseltamab | Multiple Myeloma | 387 | 2019-01-23 | 2033-03-30 | in 2,414 d | 2026-04-20 |
| PFE | Pfizer | $155.3B | Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantNCT05317416Progression Free Survival | Phase 3 | Active, not recruiting | Drug: Elranatamab, Lenalidomide, Lenalidomide, Elranatamab | Multiple Myeloma | 854 | 2022-03-25 | 2027-08-04 | in 349 d | 2026-04-16 |
| BMY | Bristol-Myers Squibb | $134.9B | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabNCT02719613The number of participants who received at least one dose of elotuzumab or backbone therapy (other study drugs) and the duration of treatment will be collected. | Phase 2 | Completed | Drug: Elotuzumab, Dexamethasone, Dexamethasone, Lenalidomide, Bortezomib, Pomalidomide, Nivolumab | Multiple Myeloma | 67 | 2016-07-15 | 2026-02-23actual | — | 2026-04-15 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple MyelomaNCT05955508Frequency of Adverse Events of Special Interest (AESI) during the safety run-in observation period | Phase 2 | Active, not recruiting | Drug: Linvoseltamab | Smoldering Multiple Myeloma (SMM) | 40 | 2024-01-30 | 2033-01-25 | in 2,350 d | 2026-04-13 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)NCT05552976Progression-free Survival (PFS) | Phase 3 | Active, not recruiting | Drug: Mezigdomide, Carfilzomib, Dexamethasone | Relapsed or Refractory Multiple Myeloma | 606 | 2023-01-10 | 2026-07-18 | — | 2026-04-01 |
| ABBV | AbbVie | $457.5B | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT06223516Percentage of Participants Experiencing Cytokine Release Syndrome (CRS) Events | Phase 1 | Active, not recruiting | Drug: Subcutaneous (SC) Etentamig, Intravenous (IV) Etentamig | Multiple Myeloma | 60 | 2024-06-17 | Feb 2027 | ≤ 192 d | 2026-03-27 |
| CCCC | C4 Therapeutics, Inc. | $514M | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple MyelomaNCT04756726Phase 1: Safety and tolerability of cemsidomide | Phase 1 | Active, not recruiting | Drug: cemsidomide, Dexamethasone Oral | Multiple Myeloma, Lymphoma, Non-Hodgkin's | 224 | 2021-04-27 | 2026-09-30 | in 41 d | 2026-03-25 |
| CLRB | Cellectar Biosciences, Inc. | $24M | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in WaldenstromNCT02952508Part A [CLOVER-1] Clinical benefit rate | Phase 2 | Active, not recruiting | Drug: Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose | Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Central Nervous System Lymphoma | 120 | 2017-07-26 | 2026-06-22 | — | 2026-03-18 |
| CRBU | Caribou Biosciences, Inc. | $167M | Long-Term Follow-up StudyNCT05332054observationalIncidence of targeted NSAEs | — | Enrolling by invitation | Biological: Caribou-sponsored investigational therapy | Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B-Cell Non-Hodgkin's Lymphoma, Hematologic Malignancy, Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Acute Myeloid Leukemia | 150 | 2022-03-16 | Dec 2041 | ≤ 5,612 d | 2026-03-12 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaNCT05730036Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC) in CD38 antibody exposed participants | Phase 3 | Recruiting | Drug: Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone | Relapsed Refractory Multiple Myeloma (RRMM) | 410 | 2023-09-18 | 2033-04-19 | in 2,434 d | 2026-03-06 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Karyopharm Expanded Access Program for SelinexorNCT07215832expanded access | — | Available | Drug: selinexor | Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma, Peripheral T-cell Lymphoma, Endometrial Cancer, Myelofibrosis, Other | — | — | — | — | 2026-03-02 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to TreatmentNCT05014412results2024-07-30Number of Participants With Grade 2 or Higher Cytokine Release Syndrome (CRS) During Cycle 1: Parts 1 and 2 | Phase 2 | Completed | Drug: Elranatamab | Multiple Myeloma | 86 | 2021-10-07 | 2023-06-15actual | — | 2026-02-10 |
| ABBV | AbbVie | $457.5B | A Study of TNB-383B in Participants With Relapsed or Refractory Multiple MyelomaNCT03933735Number of Participants with Dose-limiting toxicities (DLT) | Phase 1/2 | Active, not recruiting | Drug: TNB-383B | Multiple Myeloma | 220 | 2019-06-24 | May 2026 | — | 2026-02-06 |
| ABBV | AbbVie | $457.5B | Expanded Access to VenetoclaxNCT03123029expanded access | — | Available | Drug: Venetoclax | Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia (ALL), Amyloidosis, Plasma Cell Leukemia | — | — | — | — | 2026-01-30 |
| BMY | Bristol-Myers Squibb | $134.9B | Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyNCT06357754observationalParticipant in situ hybridization (ISH) or droplet-based digital Polymerase chain reaction (ddPCR) transgene testing results | — | Recruiting | Biological: Idecabtagene vicleucel, Lisocabtagene maraleucel | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma | 50 | 2023-10-06 | 2038-10-06 | in 4,430 d | 2026-01-22 |
| BLRX | BioLineRx, Ltd. | — | A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)NCT03246529results2023-11-07Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis Sessions | Phase 3 | Active, not recruiting | Drug: BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF | Multiple Myeloma | 180 | 2018-03-23 | 2020-12-22actual | — | 2026-01-15 |
| PFE | Pfizer | $155.3B | A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.NCT05228470results2024-09-19Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) | Phase 2 | Completed | Drug: Elranatamab | Elranatamab, Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma, PF-06863135, BCMA, Bispecific, Bispecific Antibody, BCMA-CD3 Bispecific, MagnetisMM-8 | 39 | 2021-12-21 | 2023-08-06actual | — | 2026-01-06 |
| SNY | Sanofi | — | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaNCT05704049Overall response rate (ORR) - Cohorts 1 to 3 | Phase 2 | Active, not recruiting | Drug: Isatuximab, Carfilzomib, Dexamethasone, Dexamethasone IV, Montelukast, Acetaminophen, Diphenhydramine, Methylprednisolone | Relapsed/Refractory Multiple Myeloma | 118 | 2023-04-05 | 2025-12-22actual | — | 2025-12-29 |
| FATE | Fate Therapeutics | $307M | FT576 in Subjects With Multiple MyelomaNCT05182073Incidence and nature of DLTs within each dose-escalation cohort to determine the MTD or MAD | Phase 1 | Completed | Drug: FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine, Daratumumab, Bendamustine | Multiple Myeloma, Myeloma | 31 | 2021-11-10 | 2024-09-20actual | — | 2025-12-12 |
| BMY | Bristol-Myers Squibb | $134.9B | Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)NCT01838512observationalOverall Survival (OS) for participants with relapsed/refractory multiple myeloma (RRMM) | — | Active, not recruiting | — | Multiple Myeloma | 2,555 | 2012-06-13 | 2030-03-31 | in 1,319 d | 2025-12-02 |
| RNAC | Cartesian Therapeutics | $278M | Descartes-15 for Patients With Relapsed/Refractory Multiple MyelomaNCT06304636Determine the safety of Descartes-15 in patients with relapsed/refractory multiple myeloma (R/R MM) | Phase 1 | Terminatedsponsor's stated reason: Phase 1 enrollment completed. Further clinical development terminated | Drug: Descartes-15 | Refractory Multiple Myeloma, Relapsed Multiple Myeloma | 4 | 2024-06-19 | 2025-04-14actual | — | 2025-11-24 |
| PFE | Pfizer | $155.3B | Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).NCT06581848observationalIncidence of an adverse event (AE)/ adverse drug reaction (ADR) | — | Active, not recruiting | Drug: Elranatamab | Multiple Myeloma | 150 | 2025-06-05 | 2030-01-31 | in 1,260 d | 2025-11-24 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)NCT05164250expanded access | — | Approved for marketing | Drug: REGN5458 | Multiple Myeloma | — | — | — | — | 2025-11-10 |
| INCY | Incyte Corporation | $24.7B | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple MyelomaNCT03837509results2023-03-20Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1/2 | Terminatedsponsor's stated reason: This decision follows recruitment difficulties. No safety-related concerns impacted this decision. | Drug: INCB001158 · Biological: Daratumumab SC | Relapsed or Refractory Multiple Myeloma | 15 | 2019-09-25 | 2022-04-05actual | — | 2025-11-04 |
| BMY | Bristol-Myers Squibb | $134.9B | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaNCT01592370results2022-02-17Number of Participants That Experienced Drug Related Grade 3-4 AEs | Phase 1/2 | Completed | Biological: Nivolumab, Ipilimumab, Lirilumab, Daratumumab · Drug: Pomalidomide, Dexamethasone | Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma | 320 | 2012-08-02 | 2020-09-25actual | — | 2025-10-22 |
| INCY | Incyte Corporation | $24.7B | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple MyelomaNCT04582539results2025-10-22Number of Participants With Any Treatment-emergent Adverse Event (TEAE) | Phase 1/2 | Terminatedsponsor's stated reason: Strategic Business Decision | Drug: INCB000928 | Myelodysplastic Syndromes, Multiple Myeloma, Anemia | 22 | 2021-08-19 | 2024-08-15actual | — | 2025-10-22 |
| AMGN | Amgen | $229.9B | A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaNCT03287908Number of subjects with dose-limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: business decision, not safety reasons. | Drug: AMG 701, Pomalidomide, Dexamethasone | Relapsed/Refractory Multiple Myeloma | 174 | 2017-11-13 | 2023-06-30actual | — | 2025-10-08 |
| PFE | Pfizer | $155.3B | Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.NCT06479954observationalIncidence of CRS events in adverse drug reaction | — | Active, not recruiting | — | Relapsed and Refractory Multiple Myeloma (RRMM) | 1 | 2024-07-30 | 2027-02-25 | in 189 d | 2025-10-02 |
| CRBU | Caribou Biosciences, Inc. | $167M | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaNCT05722418(Part A) Number of patients with dose limiting toxicities (DLT) | Phase 1 | Recruiting | Biological: CB-011 | Relapsed/Refractory Multiple Myeloma | 50 | 2023-02-06 | Dec 2027 | ≤ 498 d | 2025-09-25 |
| CGEM | Cullinan Therapeutics Inc. | $1.3B | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple MyelomaNCT06381141Proportion of participants reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: CLN-619 | Multiple Myeloma | 30 | 2024-09-03 | Sep 2026 | ≤ 41 d | 2025-09-18 |
| SNY | Sanofi | — | Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)NCT04045795Assessment of adverse events (AEs) | Phase 1 | Completed | Drug: isatuximab SAR650984 IV, pomalidomide, dexamethasone, isatuximab SAR650984 SC · Device: Investigational injector device | Multiple Myeloma | 56 | 2019-08-06 | 2024-03-27actual | — | 2025-09-12 |
| AMGN | Amgen | $229.9B | Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple MyelomaNCT03836053results2024-01-05Number of Participants With Dose-limiting Toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Amgen re-evaluated the portfolio and decided to discontinue clinical development activities for AMG 420. | Drug: AMG 420 | Relapsed and/or Refractory Multiple Myeloma | 23 | 2019-03-04 | 2022-04-21actual | — | 2025-09-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaNCT05372354Number of participants with adverse events (AEs) | Phase 1/2 | Recruiting | Drug: CC-92480, Tazemetostat, BMS-986158, Trametinib, Dexamethasone | Multiple Myeloma | 260 | 2022-10-18 | 2026-10-12 | in 53 d | 2025-09-05 |
| AMGN | Amgen | $229.9B | Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib TripletNCT04191616results2023-11-08Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) | Phase 2 | Completed | Drug: Carfilzomib, Dexamethasone, Pomalidomide | Relapsed or Refractory Multiple Myeloma | 54 | 2020-08-06 | 2022-11-30actual | — | 2025-09-04 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced MalignanciesNCT04772989Percentage of participants with Adverse Events | Phase 1 | Completed | Drug: AB308, Zimberelimab | Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer, Multiple Myeloma, Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma (DLBCL), Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 94 | 2021-03-19 | 2025-08-25actual | — | 2025-08-28 |
| ABBV | AbbVie | $457.5B | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple MyelomaNCT03314181Overall Response Rate (ORR) | Phase 2 | Active, not recruiting | Drug: Dexamethasone, Daratumumab, Venetoclax, Bortezomib | Multiple Myeloma | 156 | 2018-04-02 | May 2031 | ≤ 1,745 d | 2025-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 TabletsNCT05308654Overall Response Rate (ORR) per International Myeloma Working Group (IMWG) Criteria | Phase 1 | Active, not recruiting | Drug: ABBV-453, Dexamethasone, Daratumumab, Lenalidomide | Relapsed/Refractory Multiple Myeloma | 34 | 2022-05-17 | 2024-02-07actual | — | 2025-08-14 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in JapanNCT05286229Number of Dose-Limiting Toxicities (DLT) | Phase 1 | Active, not recruiting | Drug: Etentamig | Relapsed/Refractory Multiple Myeloma | 8 | 2022-03-24 | Mar 2026 | — | 2025-08-08 |
| ABBV | AbbVie | $457.5B | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)NCT02899052Number of Participants with Adverse Events | Phase 2 | Active, not recruiting | Drug: Carfilzomib, Venetoclax, Dexamethasone | Multiple Myeloma | 120 | 2017-01-19 | Jun 2027 | ≤ 314 d | 2025-08-05 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in TaiwanNCT06163040observationalNumber of participants with adverse events | — | Completed | Drug: Elotuzumab in combination with pomalidomide and dexamethasone, Elotuzumab in combination with lenalidomide and dexamethasone | Relapsed or Refractory Multiple Myeloma | 7 | 2023-12-22 | 2025-03-17actual | — | 2025-07-31 |
| AMGN | Amgen | $229.9B | AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid LeukemiaNCT02675452results2025-07-09Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) | Phase 1 | Terminatedsponsor's stated reason: sponsor decision, unrelated to safety | Drug: AMG 176, Azacitidine, Itraconazole | Relapsed or Refractory Multiple Myeloma, Relapsed or Refractory Acute Myeloid Leukemia | 141 | 2016-06-13 | 2024-05-27actual | — | 2025-07-09 |
| BMEA | Biomea Fusion Inc. | $98M | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLNCT05153330Determine Optimal Biologic Dose (OBD) and RP2D of BMF-219 monotherapy for (Cohorts 1, 2, 3 & 4) | Phase 1 | Terminatedsponsor's stated reason: Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or efficacy observations led to this study closure. | Drug: BMF-219 | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Mixed-Phenotype Leukemia, Cancer, Refractory, Progression, Diffuse Large B Cell Lymphoma, Multiple Myeloma, Lymphoma, Lymphoma, Non-Hodgkin, Myeloma, Plasma-Cell, Myelomatosis, Plasma Cell Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 55 | 2022-01-24 | 2025-02-13actual | — | 2025-07-03 |
| PFE | Pfizer | $155.3B | A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and USNCT06504524results2025-06-27observationalOverall Survival (OS): C1071003 Cohort A Versus TM-MM Database Using Inverse Probability of Treatment Weights (IPTW) Analysis | — | Completed | Drug: Elranatamab, Standard of Care | Multiple Myeloma | 633 | 2023-09-01 | 2024-05-31actual | — | 2025-06-27 |
| ABBV | AbbVie | $457.5B | A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.NCT03539744Progression-Free Survival (PFS) | Phase 3 | Active, not recruiting | Drug: Pomalidomide, Dexamethasone, Venetoclax | Multiple Myeloma | 265 | 2018-10-22 | Aug 2026 | ≤ 11 d | 2025-06-19 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care TherapiesNCT06592222observationalProgression-free survival | — | Completed | Drug: Elranatamab, Standard of care | Multiple Myeloma | 4 | 2024-08-26 | 2025-03-03actual | — | 2025-05-20 |
| ABBV | AbbVie | $457.5B | Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT04570631Recommended Phase 2 Dose (RP2D) of Eftozanermin Alfa in Combination With Bortezomib and Dexamethasone (Safety Lead-In Arm) | Phase 1 | Terminatedsponsor's stated reason: Strategic considerations | Drug: Eftozanermin alfa, Bortezomib, Dexamethasone | Multiple Myeloma | 4 | 2020-11-05 | 2025-05-05actual | — | 2025-05-16 |
| RNAC | Cartesian Therapeutics | $278M | Descartes-11 in Patients With Relapsed/Refractory Multiple MyelomaNCT03994705results2025-04-25Number of Participants With Treatment-Related Adverse Events | Phase 1 | Terminatedsponsor's stated reason: Phase 1 enrollment completed. Further clinical development terminated. | Biological: Descartes-11 · Drug: Fludarabine, Cyclophosphamide | Multiple Myeloma | 20 | 2019-08-01 | 2021-05-27actual | — | 2025-05-15 |
| AMGN | Amgen | $229.9B | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.NCT03158688results2020-09-11Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) | Phase 3 | Completed | Drug: Dexamethasone, Daratumumab, Carfilzomib | Relapsed Multiple Myeloma, Refractory Multiple Myeloma | 466 | 2017-06-13 | 2019-07-14actual | — | 2025-05-09 |
| GILD | Gilead Sciences | $177.9B | Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaNCT04892446results2025-05-02Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Phase 2 | Terminatedsponsor's stated reason: This study was terminated early due to the Sponsor's decision to discontinue development of the investigational drug and close the program. | Drug: Magrolimab, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib | Multiple Myeloma | 36 | 2021-11-09 | 2024-04-25actual | — | 2025-05-02 |
| REGN | Regeneron Pharmaceuticals | $76.1B | Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple MyelomaNCT05673967observationalProportion of patients exposed to each type of regimen by line of therapy (LOT) | — | Completed | Other: Non-Interventional | Relapsed and Refractory Multiple Myeloma (RRMM) | 62 | 2023-01-09 | 2024-09-12actual | — | 2025-04-25 |
| ORIC | ORIC Pharmaceuticals | $1.4B | Study of ORIC-533 in Relapsed or Refractory Multiple MyelomaNCT05227144Recommended Phase 2 Dose (RP2D) | Phase 1 | Completed | Drug: ORIC-533 | Relapsed or Refractory Multiple Myeloma | 31 | 2022-01-06 | 2025-03-03actual | — | 2025-03-20 |
| KPTI | Karyopharm Therapeutics Inc | $44M | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsNCT02649790Part A1, A2, B, C, D, E, F: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | Phase 1/2 | Completed | Drug: KPT-8602, ASTX727, Dexamethasone | Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS | 277 | Jan 2016 | 2024-08-31actual | — | 2025-03-19 |
| PFE | Pfizer | $155.3B | PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple MyelomaNCT03269136results2025-03-18Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v)4.03 | Phase 1 | Completed | Drug: PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide, PF-06863135 + pomalidomide | Multiple Myeloma | 101 | 2017-11-29 | 2024-01-19actual | — | 2025-03-18 |
| PFE | Pfizer | $155.3B | Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)NCT05238311expanded access | — | No longer available | Drug: Elranatamab | Multiple Myeloma | — | — | — | — | 2025-02-04 |
| CRSP | CRISPR Therapeutics AG | $5.1B | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple MyelomaNCT04244656Part A (dose escalation): Incidence of adverse events | Phase 1 | Terminatedsponsor's stated reason: Patients to be followed up in the CRSP-ONC-LTF study | Biological: CTX120 | Multiple Myeloma | 26 | 2020-01-22 | 2024-01-04actual | — | 2025-01-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Multiple Myeloma is matched — 18 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Multiple Myeloma
- Relapsed/Refractory Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
- Relapsed Multiple Myeloma
- Multiple Myeloma (MM)
- Refractory Multiple Myeloma
- Relapse Multiple Myeloma
- Relapsed and/or Refractory Multiple Myeloma
- Advanced Multiple Myeloma
- Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Multiple Myeloma in Relapse
- Relapsed Refractory Multiple Myeloma
- Relapsed Refractory Multiple Myeloma (RRMM)
- Relapsed and Refractory Multiple Myeloma
- Relapsed and Refractory Multiple Myeloma (RRMM)
- Relapsed/Refractory Multiple Myeloma (RRMM)
- Smoldering Multiple Myeloma
- Smoldering Multiple Myeloma (SMM)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Multiple Myeloma” (a text search, wider than this page)